Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 410.51A Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
10 (6*) |
| Average PDX Generation Time (days +/- SEM) | 108 ± 9 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 410.51A Cx |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 410.51A Cx | AKT3 | 1.135 | 4.392 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | BRAF | 0.882 | 3.687 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | CHD7 | 0.871 | 3.657 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | EZH2 | 0.523 | 2.875 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | GNAS | 0.507 | 2.843 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | IDH1 | 0.567 | 2.963 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | KMT2C | 0.523 | 2.875 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | MET | 0.504 | 2.836 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | MYC | 0.860 | 3.630 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | PIK3CB | 0.716 | 3.284 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | RB1 | -1.556 | 0.680 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | RB1 | -1.394 | 0.761 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 410.51A Cx | SETDB1 | 0.564 | 2.958 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 410.51A |
|---|---|
| Sample Site | Right lung sub pleural tumour |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
Patient Information
| Patient Number | 410 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 30 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 410.51A |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 410.51A Cx | AKT3 | 176 | 0.85 | Missense variant | '3/14 | . | 28.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 410.51A Cx | GATA3 | 83 | 0.49 | Missense variant | '3/6 | 8.26E-06 | 26.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 410.51A Cx | ZNF703 | 200 | 0.44 | Missense variant | '1/2 | 0.0002802 | 28.6 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 410.51A Cx | CRLF2 | 115 | 0.27 | Missense variant | '6/6 | . | 9.837 | Not provided | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 410.51A Cx | ASXL1 | 250 | 0.26 | Missense variant | '12/13 | . | 26 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table